Exploring Potential Biomarkers and Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma Based on Bioinformatics
Jiayue Qi,Qingqing Guo,Jia Bai,Xiaoqiang Liang,Wenwei Zhu,Chengxin Li,Fang Xie
DOI: https://doi.org/10.2147/ott.s468399
IF: 4
2024-10-26
OncoTargets and Therapy
Abstract:Jiayue Qi, 1, 2 Qingqing Guo, 1, 2 Jia Bai, 1 Xiaoqiang Liang, 1 Wenwei Zhu, 1 Chengxin Li, 1, 2, &ast Fang Xie 1, &ast 1 Department of Dermatology, First Medical Center, Chinese PLA General Hospital, Beijing, People's Republic of China; 2 School of Medicine, Nankai University, Tianjin, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chengxin Li; Fang Xie, Department of Dermatology, First Medical Center, Chinese PLA General Hospital, Beijing, 100853, People's Republic of China, Email ; Purpose: Cutaneous squamous cell carcinoma (cSCC) ranks as the second most common malignancy in clinical practice and poses a significant threat to public health due to its high malignancy. In this study, we aimed to explore potential biomarkers and molecular mechanisms of cSCC. Methods: Differentially expressed genes (DEGs) from GSE66359 and GSE117247 datasets were identified using R software. We conducted enrichment analyses and screened hub genes through protein-protein interaction (PPI) analysis and weighted gene co-expression network analysis (WGCNA). To assess the diagnostic performance of these genes, we generated ROC curves using both internal and external datasets (GSE45164) and validated the expression levels of these genes in cSCC tissues through immunohistochemistry. Subsequently, we predicted the target miRNAs and lncRNAs for hub genes using online databases and constructed competing endogenous RNA (ceRNA) networks. Results: In total, we identified 505 upregulated DEGs and 522 downregulated DEGs. Through PPI and WGCNA analyses, we identified four hub genes exhibiting robust diagnostic performance in internal and external datasets (AUC > 0.9) and selected three previously unreported genes for further analysis. Immunohistochemistry demonstrated significantly elevated CCNA2, CCNB2, and UBE2C expression in cSCC tissues compared to normal skin tissues. Finally, we constructed three ceRNA networks, namely NEAT1/H19-hsa-miR-148a-3p-CCNA2 and NEAT1-hsa-miR-140-3p-UBE2C. Conclusion: In conclusion, we have identified CCNA2, CCNB2, and UBE2C as novel biomarkers for cSCC, and the NEAT1/H19-hsa-miR-148a-3p-CCNA2 and NEAT1-hsa-miR-140-3p-UBE2C ceRNA networks may represent molecular mechanisms under-lying cSCC progression. The findings of this study offer new diagnostic and therapeutic options for cSCC patients. Keywords: weighted gene co-expression network analysis, protein-protein interaction analysis, competitive endogenous RNA, pathogenesis Cutaneous squamous cell carcinoma (cSCC), originating from epidermal keratinocytes, ranks as the second most prevalent malignant cutaneous neoplasm in clinical practice, constituting approximately 20–50% of all skin malignancies. 1 It exhibits a propensity for metastasis, disseminating to lymph nodes and various organs, including the liver, lungs, and bones, posing a substantial threat to life. 2 In recent years, the incidence of cSCC has gradually increased, owing to its heightened malignancy, thereby representing a significant menace to public health. 3 Despite certain advancements in diagnosis and treatment, there remains a lack of comprehensive understanding regarding the pathogenesis of cSCC, and satisfactory therapeutic efficacy still needs to be discovered, with long-term survival rates of treated patients falling below 20%. 4 Consequently, there is a pressing need for further exploration of novel, effective biomarkers, augmenting our comprehension of the pathogenesis of cSCC, and offering fresh diagnostic and therapeutic alternatives for cSCC patients. Currently, transcriptomics and chip analysis have found widespread application in various diseases. 5–7 Differentially expressed genes analysis is a quantitative approach for investigating changes in gene expression levels between experimental and control groups in multiple samples. 8 It is extensively employed to identify potential biomarkers and therapeutic targets for cancer. Another crucial analysis in transcriptomics is weighted gene co-expression network analysis (WGCNA), which allows the examination of gene expression patterns, identification of co-expression modules containing highly correlated genes, and modules associated with clinical traits. 9 Consequently, integrating WGCNA and differentially expressed gene analysis results can enhance the precision in identifying potential hub genes in cSCC. Furthermore, competitive endogenous RNA (ceRNA) networks can elucidate novel mechanisms that promote cSCC development within the transcriptional regulatory network.<sup -Abstract Truncated-
oncology,biotechnology & applied microbiology